ACECAINIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H23N3O2
Molecular Weight	277.362
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1

InChI

InChIKey=KEECCEWTUVWFCV-UHFFFAOYSA-N

InChI=1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)

HIDE SMILES / InChI

Molecular Formula	C15H23N3O2
Molecular Weight	277.362
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1693889 | https://www.ncbi.nlm.nih.gov/pubmed/9730262 | https://www.ncbi.nlm.nih.gov/pubmed/6188570 | https://adisinsight.springer.com/drugs/800000315 | https://www.ncbi.nlm.nih.gov/pubmed/11245854

Acecainide (N-acetylprocainamide), the N-acetylated metabolite of procainamide, is a Class III antiarrhythmic agent. Acecainide exerts cardiac anticholinergic effect. It elicits smooth muscle relaxation mainly through the activation of plasma membrane K+ channels. Acecainide markedly reduced premature ventricular beats and prevented induction of ventricular tachycardia. Acecainide appears to offer advantages over procainamide, particularly with respect to the reduced formation of antinuclear antibodies. Acecainide development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium channel 4 Target ID: Potassium channel Sources: https://adisinsight.springer.com/drugs/800000315 \| https://www.ncbi.nlm.nih.gov/pubmed/11245854	Antagonist 2778

PubMed

Title	Date	PubMed
Torsade de pointes associated with elevated N-acetylprocainamide levels.	1985 Feb	2578241
Polymorphic ventricular tachycardia and ventricular fibrillation due to N-acetyl procainamide.	1985 Jan 1	2578244
Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma.	2006 Jan	16221756
Effect of drugs on defibrillation capacity.	2008	18370441
Drug therapy considerations in arrhythmias in children.	2008 Aug 1	18679519
Procainamide, but not N-acetylprocainamide, induces protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis.	2008 May	18489081
The prince and the pauper. A tale of anticancer targeted agents.	2008 Oct 23	18947424
Overview of therapeutic drug monitoring.	2009 Mar	19270474

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 07:44:01 GMT 2023` Edited by `admin` on `Sat Dec 16 07:44:01 GMT 2023`
Record UNII	910Q707V6F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACECAINIDE

Official Name

English

N-ACETYL-PROCAINAMIDE

Common Name

English

BENZAMIDE, 4-(ACETYLAMINO)-N-(2-(DIETHYLAMINO)ETHYL)-

Systematic Name

English

4'-((2-(DIETHYLAMINO)ETHYL)CARBAMOYL)ACETANILIDE

Systematic Name

English

N-ACETYLNOVOCAINAMIDE

Common Name

English

Acecainide [WHO-DD]

Common Name

English

N-ACETYLPROCAINAMIDE

Common Name

English

ACECAINIDE [MI]

Common Name

English

acecainide [INN]

Common Name

English

ACETYLPROCAINAMIDE, N-

Common Name

English

N-ACETYLPROCAINE AMIDE

Common Name

English

ACETYLPROCAINAMIDE

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

35989